Discontinued label guidance
Executive Summary
FDA guidance on allowing ANDAs to reference discontinued labeling from listed drugs is understood to be under review by the office of Chief Counsel Daniel Troy. The guidance would affect the approval of generic versions of drugs that have been recently re-labeled. Pediatric labeling changes are delaying approval of generics for Bristol's BuSpar and Glucophage (1"The Pink Sheet" Oct. 1, p. 26)
You may also be interested in...
J&J Says Ultram Titration Schedule Was Developed To Improve Safety Profile
A titration dosing regimen for Johnson & Johnson's analgesic Ultram was added to the non-titrated dosing schedule in labeling in order to reduce adverse events, J&J told FDA
J&J Says Ultram Titration Schedule Was Developed To Improve Safety Profile
A titration dosing regimen for Johnson & Johnson's analgesic Ultram was added to the non-titrated dosing schedule in labeling in order to reduce adverse events, J&J told FDA
J&J Ultram Titration Relabeling Should Not Block Generics, Apotex Argues
Apotex' citizen petition requesting approval of generic Ultram argues that Johnson & Johnson did not make labeling changes for safety or efficacy reasons